Designing Tomorrow's Vaccines
Open accessAbstract
an nejm app for iphoneThe NEJM Image Challenge app brings a popular online feature to the smartphone.Optimized for viewing on the iPhone and iPod Touch, the Image Challenge app lets you test your diagnostic skills anytime, anywhere.The Image Challenge app randomly selects from 300 challenging clinical photos published in NEJM, with a new image added each week.View an image, choose your answer, get immediate feedback, and see how others answered.The Image Challenge app is available at the iTunes App Store.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vaccines based on mRNA offer multifaceted advantages including flexible antigen design, a cost-effective manufacturing process allowing for parallel production of multiple mRNA vaccines, and rapid manufacturing.
“Vaccines based on mRNA could meet these requirements because they offer multifaceted advantages including flexible antigen design, a cost-effective manufacturing process allowing for parallel production of multiple mRNA vaccines1–5 and rapid manufacturing, which could be of crucial importance during pandemics.6”
From Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines (2017) · cites this paper as [5]
The opening section says older vaccine technologies were ill-suited to a rapid response to the 2009 H1N1 pandemic, but it does not say mRNA vaccines can be manufactured rapidly. The passages on manufacturing and gene-based delivery likewise do not address mRNA vaccine production, its cost, or parallel production (searched: mRNA vaccines, messenger RNA, rapid manufacturing). (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 50 · Cited by 271
- Authors
- Nabel, G. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Nabel, Gary J.
- ORCID
- Nabel, Gary J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-07
- Volume
- 368
- Issue
- 6
- Pages
- 551-560
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3612922
- OpenAlex
- W2027210355
- Cited by
- 271
- References
- 50
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 17 · 2022: 11 · 2021: 22 · 2020: 33 · 2019: 15 · 2018: 23 · 2017: 19 · 2016: 21 · 2015: 37 · 2014: 30 · 2013: 20 · 2012: 1
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Sanofi
- National Institutes of Health (Z99 AI999999)
- National Institute of Allergy and Infectious Diseases (Y99 AI999999, ZIAAI005002, Z01AI005003, Z01AI005002, ZIAAI005058, ZIAAI005003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- vaccine design, vaccines
- MeSH terms
- Allergy and Immunology, Clinical Trials as Topic, Communicable Disease Control, Communicable Diseases, Dendritic Cells, Humans, Licensure, Vaccines, Drug Design, Evolution, Molecular, History, 19th Century, History, 20th Century, History, 21st Century, Host-Pathogen Interactions, Antibodies, Neutralizing, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
